A total of 29 significant adverse event signals were identified from 592 reports associated with cefiderocol in the database.
Cefiderocol was linked to adverse events across 24 different organ systems.
Notable adverse events included Pathogen resistance, Systemic candida, and Drug resistance.
The reporting odds ratio (ROR) for Pathogen resistance was 189.35, indicating a strong signal of disproportionate reporting.
Death, Drug resistance, and Treatment failure were the most frequently observed adverse events associated with cefiderocol.
The findings suggest a need for heightened awareness among clinicians and pharmacists regarding cefiderocol's safety profile.
Simplified
BACKGROUND: Cefiderocol is a new drug class, which is approved to treat Gram-negative bacteria infection. Its approval for marketing has provided clinicians with additional options for treating antimicrobial resistant gram-negative infections. The aim of our study was to assess the safety profiles of cefiderocol in real-world through data mining of the United States Food and Drug Administration (FAERS).
METHODS: We included adverse event (AE) reports regarding cefiderocol submitted to the FAERS from 2019 quarter 4 (2019Q4) to 2024 quarter 3 (2024Q3). Disproportionality analyses, including reporting odds ratio (ROR), proportional reporting ratio (PRR), Bayesian Confidence Propagation Neural Network (BCPNN) and Multi-item Gamma Poisson Shrinker (MGPS) techniques were performed to identify the signals of disproportionate reporting of AEs in patients receiving cefiderocol. A signal of disproportionate reporting was detected if the lower limit of the 95% confidence interval (CI) of ROR > 1, the PRR was ≥ 2(while the Chi-Square of PRR was ≥ 4), the lower limit of 95% CI of the information component (IC025) was > 0, the lower limit of 95% CI of the Empirical Bayes Geometric Mean (EBGM05) was > 2 and at least 3 AEs were reported.
RESULTS: A total of 29 significant preferred terms (PTs) were identified among the 592 cefiderocol-associated adverse events (AEs) reports collected from the FAERS database. Cefiderocol-induced adverse events involved 24 System Organ Class (SOC). 29 positive signals of disproportionate reporting are also presented, such as Pathogen resistance (n = 16, ROR 189.35, PRR 184.26, IC 7.52, EBGM 183.89), Systemic candida (n = 3, ROR 138.79, PRR 138.19, IC7.11, EBGM 137.88), Drug resistance (n = 30, ROR 131.96, PRR 125.33, IC6.97, EBGM 125.16), and Drug effect less than expected (n = 6, ROR 68.42, PRR 67.74, IC6.08, EBGM 67.69). The most frequently observed were Death, Drug resistance and Treatment failure.
CONCLUSIONS: Our findings offer significant evidence regarding the safety profile of cefiderocol in real-world settings. This information may assist clinicians and pharmacists in enhancing their vigilance and improving the overall safety of cefiderocol in clinical practice.
Key numbers
592
Adverse Events Reports
Total adverse events reports associated with cefiderocol from .
189.35
Pathogen Resistance ROR
Reporting odds ratio indicating strong association with cefiderocol use.
54.61%
Death Reports Percentage
Percentage of adverse event reports related to death among cefiderocol users.
Full Text
We can’t show the full text here under this license.
Declarations. Ethical approval: Not applicable. Consent to participate: The requirement for obtaining individual patient consent was waived as the study did not have an impact on clinical care and all protected health information was de-identified. Consent for publication: Not applicable. Competing interests: The authors declare no competing interests.
PubMed
Weekly GLP-1 Therapies Brief
You found one interesting study. We’ll send the next 7.
Get 7 new glp-1 therapies papers each week, explained in plain English with direct links to the originals.
